



TCR² Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference

Cambridge, MA, February 28, 2017 – TCR² Therapeutics Inc. announced today that its Chief Executive Officer, Garry E. Menzel, Ph.D., will present a company overview at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017 at 12:00 PM Eastern Time. The event will be held in Boston at the Marriott Copley Place.

About TCR² Therapeutics

TCR² Therapeutics is an immuno-oncology company developing novel cancer therapies that unleash the full signaling power of complete T cell receptors (TCR). TCR² has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. The company has demonstrated activity against both hematological and solid tumor targets in preclinical models and believes its TRuC™-reprogrammed T cells will serve as the engine for important therapies. TCR² was founded in 2015 by Dr. Patrick Baeuerle and backed with a \$44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.

Media Contact:

Kathy Vincent
(310) 403-8951
kathy@kathyvincent.com

###